Home  >  Products  >  BRCA1 (breast cancer 1, early onset ) Blocking Peptide (the N terminal of BRCA1)(100ug)
BRCA1 (breast cancer 1, early onset ) Blocking Peptide (the N terminal of BRCA1)(100ug)

BRCA1 (breast cancer 1, early onset ) Blocking Peptide (the N terminal of BRCA1)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-BRCA1 Antibody (ARP30434_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAPP48825
Size: 100ug
Weight: 76kDa
Gene: The peptide is characterized by mass spectroscopy
Format: Lyophilized powder
Target: The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. BRCA1 acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. BRCA1 plays a central role in DNA repair by facilitating cellular response to DNA repair. BRCA1 is required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. BRCA1 is involved in transcriptional regulation of P21 in response to DNA damage. BRCA1 is also required for FANCD2 targeting to sites of DNA damage.It may function as a transcriptional regulator. BRCA1 inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation.
Alternative names: BRCAI; BRCC1; IRIS; PSCP; RNF53
See Full Product Listings >